SomaLogic, Inc., a provider of proteomics technology, announced that it is extending its collaborative agreement with Novo Nordisk. As part of the agreement, which now extends into the end of 2025, Novo Nordisk will expand its use of the SomaScan® proteomics platform in drug research and development. Novo Nordisk will also use SomaLogic’s SomaSignal® tests for investigations into cardiometabolic and other diseases. This extension builds upon a previous agreement between the two companies, which was announced in 2021.
“SomaLogic has been very pleased with our partnership with Novo Nordisk which spans more than a decade,” said SomaLogic Chief Executive Officer Adam Taich. “We are proud that our SomaScan platform is being used in their research and development of new potential treatments for serious chronic diseases.”
Novo Nordisk previously partnered with SomaLogic to provide proteins of interest that expanded the SomaScan platform’s previous offering to its current industry-leading offering of more than 7,000 proteins. SomaLogic’s proprietary protein detection and analysis technology measures how proteins function and interact, supporting researchers in drug research and development, and biomarker identification efforts.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!